Pharma Update slide image

Pharma Update

Susvimo: Continuous 6m delivery preferred by 93% patients vs IVT Commercial US relaunch expected in 2024 and ex-US 2025+ Stronger vision outcomes with potential for extended ≥Q6M dosing Continuous delivery of aVEGF via PD implant 1-2 refill exchanges per year • 93% of patients prefer Susvimo to IVT injections¹ Prefer IVT No Preference Prefer PDS Roche SuSvim o™ ranibizumab injection F 180mg/ml. Ongoing development for the Port Delivery Platform October 2022: SUSVIMO voluntarily recalled due to manufacturing variability; root cause identified and progress made to implement technical solution February 2023: Positive data from pivotal Ph III studies in DME (PAGODA) and DR (PAVILLION) presented at Angiogenesis: • DME: Improved vision (Q6M dosing)² DR: Superior improvement in ≥ 2-Step ETDRS-DRSS (Q9M dosing)³ Trend toward improved safety profile with evolved surgical implantation training and technique²,3 • Q4 2023: Clinical trials expected to restart • Ph lllb (VELODROME) assessing Q9M dosing in nAMD First trials of next generation bispecifics (DutaFabs) 1. Holekamp N et al. ARCHWAY Ph III Trial of the PDS for nAMD, American Academy of Ophthalmology, 129(3), 2022; 2. Campochiaro P et al. Port Delivery System With Ranibizumab in Diabetic Macular Edema: Primary Analysis Results of the Ph III PAGODA Trial, Presented at the Macula Society 46th Annual Meeting, Miami, FL, February 15-18, 2023. 3. Holekamp N et al. Port Delivery System With Ranibizumab in the Treatment of Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema: Primary Analysis Results of the Ph III PAVILION Trial, Presented at the Macula Society 46th Annual Meeting, Miami, FL, February 15-18, 2023. VEGF = Vascular Endothelial Growth Factor; Q6M-every 6 months; PD = Port Delivery; IVT-intravitreal injection; DME-diabetic macular edema; DR-diabetic retinopathy; EDTRDS-DRSS-early treatment diabetic retinopathy study-diabetic retinopathy severity scale; Q9M-every 9 months; nAMD = neovascular age related macular degeneration; 50 50
View entire presentation